Regulation of human chorionic gonadotropin beta subunit expression in ovarian cancer

Aleksandra Śliwa1*, Marta Kubiczak1†, Anna Szczerba1†, Grzegorz Walkowiak1, Ewa Nowak-Markwitz2, Beata Burczyńska3, Stephen Butler4, Ray Iles4,5, Piotr Białas1 and Anna Jankowska1

Abstract

Purpose: Expression of human chorionic gonadotropin beta subunit by cancers is extensively documented, yet regulation of the multiple genes that can code for this protein is poorly understood. The aim of the study was to examine the mechanisms regulating CGB gene expression in ovarian cancer.

Methods: Expression of CGB genes and SP1, SP3, TFAP2A transcription factor genes was evaluated by RT-qPCR. The methylation status of CGB genes promoter regions was examined by methylation-specific PCR.

Results: mRNA arising from multiple CGB genes was detected in both ovarian control and malignant tissues. However, expression of CGB3–9 genes was shown to be significantly higher in malignant than healthy ovarian tissues. CGB1 and CGB2 transcripts were shown to be present in 20% of ovarian cancers, but were not detected in any of the control samples. Malignant tissues were characterized by DNA demethylation of CGB promoter regions. In ovarian cancer CGB expression positively correlated with TFAP2A transcripts level and expression of TFAP2A transcription factor was significantly higher in cancer than in control tissues. In contrast SP3 expression level was significantly lower in ovarian tumours than in control ovarian tissue.

Conclusions: In ovarian cancers increased expression of human chorionic gonadotropin beta subunit is associated with demethylation of CGB promoter regions. CGB3–9 expression level strongly correlates with expression of the TFAP2A transcription factor. Presence of mRNA arising from CGB1 and CGB2 genes appears to be a unique feature of a subset of ovarian cancers.

Keywords: Human chorionic gonadotropin beta subunit, DNA methylation, Gene expression regulation, AP2 transcription factor, Ovarian cancer

Background

Human chorionic gonadotropin (hCG) is a hormone known for its significant role in sustaining pregnancy and survival of the foetus. In particular, it supports decidualization of the endometrium and embryo implantation. More recent studies suggest that hCG plays an important role in human placental angiogenesis and maternal immunosuppression as well as immunotolerance of the embryo [1–3].

It has also been shown that expression of hCG, in particular its free beta subunit (hCGβ), is detected in 30–60% of tumours of different origin [4]. Many studies have demonstrated that both hCG and hCGβ promote survival of cancer cells via regulation of cell proliferation, angiogenesis, and apoptosis [1–3, 5–7]. Furthermore, hCGβ secretion by a tumour is strongly associated with metastasis, resistance to therapy, which are consequently linked to poor prognosis [7]. Recently it was reported that hCGβ induces transformation of ovarian surface epithelial cells. Specifically the free hCG beta subunit has been shown to regulate the epithelial-mesenchymal transition process and support migration and invasion of cancer cells [8]. CGB overexpression by tumours was shown also to...
promote valculogenic mimicry – a rate-limiting step in metastasis of ovarian cancer [9].

Although the associations between ectopic expression of hCG/hCGβ and carcinogenesis are now established, the exact molecular mechanisms behind regulation of CGB genes that encode for this hormone’s beta-subunit remain unclear [10–17].

The beta subunit of hCG is encoded by a group of highly homologous genes (marked CGB1−CGB9) but the expression of individual CGB genes is uneven. Analysis of mRNA derived from placenta and cancer tissues pointed to a twenty fold higher transcriptional activity of CGB5 compared to CGB3 or CGB8 [18, 19].

During pregnancy CGB expression is dependent on epigenetic changes as well as expression of tissue-specific transcription factors [10–17, 20]. Studies have shown that, in placentals tissues, regions of DNA encoding the CGB gene cluster are hypo-methylated [13]. This was also true of choriocarcinoma samples. Moreover it was demonstrated that methylation sensitive allelic polymorphism in CGB5 gene promoter regions, may be associated with a higher susceptibility for miscarriage [10–12]. Our recent study also confirmed that changes in CGB genes expression, caused by deregulation of epigenetic mechanisms, is associated with increased risk of early pregnancy loss [13].

Another aspect of CGB expression regulation by the placenta is the dependency on the access to selected transcription factors: AP2, SP1, and SP3. Along with changes in the level of the three key transcription factors: AP2, SP1, and SP3, are believed to be the key regulators of basal CGB transcription in placental trophoblast cells [20–26]. In fact, we have previously shown that, during pregnancy, expression of CGB genes strongly correlates with expression of the TFAP2A gene, encoding the AP2 transcription factor [13].

In this study we examined the hypothesis that, similar to placenta, CGB expression by ovarian cancers is associated with methylation alterations of the CGB gene cluster, along with changes in the level of the three key transcription factors: AP2, SP1, and SP3.

Methods
Sample collection
Ovarian cancer tissue samples were collected from 19 patients treated by surgery at the Department of Gynaecologic Oncology, Poznan University of Medical Sciences, Poland. The histological subtypes of ovarian carcinomas were: 12 serous, 2 endometrioid, 2 undifferentiated, 2 solid appendages, 1 mucinous. UICC histological grading of the subtypes of ovarian carcinomas was as follows: G1, n = 1; G2, n = 6 and G3, n = 12 stage (Table 1).

A control group of samples consisted of 12 ovarian tissues that lacked cancerous changes, as evaluated by a clinical pathologist’s macroscopic and microscopic examination. These control tissues were obtained from postmenopausal patients who underwent total hysterectomy with additional oophorectomy due to benign myometrial and endometrial lesions.

The study was approved by the ethics review board of Poznan University of Medical Sciences (Resolution No: 748/08) and all patients participated after written informed consent.

Tissue samples obtained during surgery were stored in RNAlater (Thermo Fisher Scientific, Waltham, MA, USA) at −80 °C.

RT-qPCR assays
Total RNA was isolated from 100 to 300 mg of tissue homogenized in 1 mL of TriPure Isolation Reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s protocol. RNA concentration and quality was determined spectrophotometrically and by eletrophoresis. The material was stored at −80 °C for further analysis.

One microgram of total RNA was used as template for reverse transcription using the oligo (dT)10 primer and Transcriptor Reverse Transcriptase (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s protocol.

RT-qPCR assays were designed to assess the expression level of analyzed genes encoding human chorionic gonadotropin beta subunit as well as SP1, SP3, and TFAP2A transcription factors. CGB genes were studied in two groups: 1) genes previously considered as pseudogenes: CGB1 and CGB2 (CGB1−2), and 2) the most transcriptionally active genes: CGB3/CGB9, CGB5, CGB6/CGB7, CGB8 (CGB3−9). Hydrolysis TaqMan probes and primers used in RT-qPCR assays are presented in Table 2.

RT-qPCR was performed using LightCycler TaqMan Master or LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) on a LightCycler 2.0 Instrument (Roche Diagnostics, Mannheim, Germany). Assays were performed according to the manufacturer’s protocols.

PCR efficiencies were calculated from standard curves, which were generated using serial dilutions of a cDNA library obtained from term placenta. Relative expression of genes was normalized against hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT) expression. Data was assembled using the software 4.05 dedicated for the LightCycler 2.0.

Methylation-specific polymerase chain reaction for CGB promoter
DNA was extracted from 50 to 300 mg of tissue samples using AxyPrep Multisource Genomic DNA Miniprep Kit (Axygen, Unin City, CA, USA). DNA concentration and quality was determined using NanoDrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and by electrophoresis.

One microgram of genomic DNA was converted with bisulfite and cleaned using EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). The prepared material was stored at −20 °C for further analysis. The quality of the conversion was verified by PCR using methylation independent primers for death associated kinase 1 gene, DAPK1 (Zymo Research, Irvine, CA, USA) (Table 3).

The method used for the assessment of methylation level of CGB genes was methylation specific PCR (MSP).

The analyzed allelic CGB genes were divided into two groups. The first included CGB3/CGB9, CGB5 and CGB8 and the second consisted of CGB1 and CGB2.

Primers used in the study were designed to cover the consensus promoter regions of genes CGB3–9 and CGB1–2 respectively. Each set of primers consisted of two pairs: one designed to bind the methylated form of the given sequence (CGB1–2, CGB3–9) and the other to bind the non-methylated sequence (CGB1–2, CGB3–9). Primer sequences and reactions conditions are presented in Table 3.

After amplification, the PCR products were separated by electrophoresis in 2% agarose gel stained with ethidium bromide (0.5 μg/ml). Images were collected and analyzed with G:BOX iChemi, model XL1.4 (Syngene, Bangalore, India).

Statistical analysis
All data were analyzed using Statistica 13.3 software package (StatSoft, Kraków, Poland). As the data was not normally distributed non-parametric statistics were applied. Associations between variables in the studied groups of ovarian tumours and control ovarian tissues was assessed using Spearman’s rank correlations. The differences between the two groups were analyzed using Mann-Whitney U tests. p < 0.05 was considered to indicate statistical significance.

Results
Expression levels of CGB genes in ovarian Cancer tissue
The relative amount of CGB transcripts was evaluated between control and cancerous ovarian tissue. CGB gene cluster expression was evaluated using RT-qPCR in two assays: CGB1–2 and CGB3–9. In the first we examined CGB1 and CGB2 genes expression, and in the second, we quantified transcript levels arising from the most transcriptionally active CGB genes found in placental and choriocarcinoma tissue – CGB3/CGB9, CGB5, CGB6/CGB7, CGB8 [18, 19].

The analysis of relative expression of CGB genes, which can encode chorionic gonadotropin beta subunit protein, varied between control and ovarian tumour samples.

In the case of CGB1 and CGB2 gene transcripts, RT-qPCR assay showed that more than 20% of analyzed ovarian tumours expressed CGB1–2, but none of the control ovarian tissues contained detectable levels of these genes transcripts (Fig. 1a).

Table 2 Primers (5′ → 3′) and hydrolysis probes for RT-qPCR with the use of SYBR Green and TaqMan assays

\[ \text{Table 2} \]

| Gene     | Forward primer | Reverse primer | Hydrolysis probe |
|----------|----------------|----------------|-----------------|
| SYBR Green |                |                |                 |
| SP1      | tgaagggaaggggctcggggg | cccagggcacaagggcgg | n/a             |
| SP3      | caggtgtgtaaagtttagtgg | ccctctacgtgtgtcttc | n/a             |
| TFAP2A   | gctgtcctcaacacgttgg | acagggacacgggctttct | n/a             |
| HPRT     | tgaagagctttgaagagcagcatgc | caaatccaaacagtggctcg | n/a             |
| TaqMan   |                |                |                 |
| CGB1–2   | ggtcctgcccttgccctg | ccagacacacccctggaca | 6FAM-tcactccgtgtctctcactccccacag-BBQ |
| CGB3–9   | ggtcctgcccttgccctg | ccagacacacccctggaca | 6FAM-tcactccgtgtctctcactccccacag-BBQ |
| HPRT     |                |                |                 |

\[ * CGB3–9 and CGB1–2 hydrolysis probes were designed and manufactured by Tib Molbiol (Berlin, Germany); $^\text{b}$ degenerated base code: S-G/C, Y-C/T \]
Methylation of CGB genes promoters in control and ovarian Cancer tissues

Methylation specific PCR was used to establish the methylation patterns of CGB gene promoter regions. The allelic CGB genes were again divided into two groups. The first assay included CGB1 and CGB2 (CGB1–2) and the second one included CGB3, CGB5 and CGB8 (CGB3–9). Utilization of MSP allowed discrimination of methylated and nonmethylated DNA templates as well as quantification of methylation levels in the studied groups.

Densitometric analysis of electrophoretically separated MSP products obtained from CGB1–2 and CGB3–9 promoters demonstrated significant differences between control and ovarian cancer tissues but only in assays targeting demethylated variants of the promoter. Indeed, the use of primers recognizing non-methylated DNA confirmed that ovarian tumour tissues are characterized by a profoundly higher demethylation level in case of both CGB1–2 and CGB3–9 gene promoter regions. The differences were statistically significant (p < 0.01 and p < 0.001, respectively) (Fig. 2).

Statistical analysis of associations between methylation status of the promoters and expression of CGB genes did not show any significant correlations. Furthermore, methylation status of promoters for the analyzed genes did not correlate with stage or grade of the tumours.

Expression of SP3 and TFAP2A transcriptional factors differs in control and cancerous ovaries

The availability of transcription factors regulating CGB genes expression was assessed on RNA level with RT-qPCR. The assay, designed to quantify relative level of SP1 transcripts, showed that the analyzed groups of samples did not differ in terms of expression of this transcription factor (Fig. 3a). However, ovarian tumours were characterized by significantly lower SP3 expression than control ovarian tissue (p < 0.01) (Fig. 3b). Nevertheless, SP1 and SP3 expression level ratio did not show significant differences between the two groups (Fig. 3c).

Significant differences between control and ovarian cancer tissues were seen for the expression of the TFAP2A gene, and was higher in case of ovarian cancer tissue (p < 0.001) (Fig. 3d).

Association analysis within the group of ovarian tumours showed that the level of TFAP2A transcripts correlated positively with CGB3–9 gene expression (R = 0.67).

The expression level of these transcription factors did not correlate with the stage and grade of the tumours.

Table 3 Primers (5’→3’) and cycling conditions used in MSP

| Primer Name | Forward primer | Reverse primer | Annealing | Elongation |
|-------------|----------------|----------------|-----------|------------|
| CGB1–2 M    | gaaattaagttcgaagtcgc | cctatcaaccaataagatcg | 30 s, 51 °C | 30 s, 72 °C |
| CGB1–2 NM   | gtagaaattaagtttgaagttg | cctatcaacccataaatca | 30 s, 47 °C | 30 s, 72 °C |
| CGB3–9 M    | tggtaagttgtagttagtgc | atacccgaacatccc | 30 s, 58 °C | 30 s, 72 °C |
| CGB3–9 NM   | aattgtttagtttgatgttagt | aaaaacccaaacatatccc | 30 s, 55 °C | 30 s, 72 °C |
| DAPK        | ataggaaagtttaaggggagaggaat | ccccaaccaaacataatccccaaaccacattct | 30 s, 59 °C | 60 s, 72 °C |

M methylated variant, NM nonmethylated variant

**Fig. 1** Relative expression level of (a) CGB1–2, (b) CGB3–9 transcripts in healthy ovary and ovarian tumor tissue measured using RT-qPCR
Discussion
It has been known for some time that, not only gynecological cancers but also other tumours of many different origin are capable of secreting hCG and especially its free beta subunit. However, the regulation of CGB genes expression as well as the role of hCGβ protein in tumorigenesis have not been satisfactorily established.

It has been shown that both epigenetic and transcription factors might regulate the genes encoding human chorionic gonadotropin beta subunit. However, most of the studies regarding CGB expression have been conducted on trophoblasts cells or choriocarcinoma cell lines in vitro and not epithelial carcinomas.

In this study we have investigated the mechanisms regulating the expression of human chorionic gonadotropin beta subunit in non-trophoblastic cancer, specifically epithelial ovarian cancer tissues. For this purpose two complementary assays were adopted. First we analyzed epigenetic changes of CGB promoter fragments and in the next step we determined the expression levels of key transcription factors involved in the regulation of CGB expression. The data obtained were correlated with CGB mRNA levels. CGB genes expression on RNA level
was analyzed in two groups. The first included CGB1 and CGB2 genes, the second consisted of the more transcriptionally active genes reported in placental studies: CGB3/CGB9, CGB5, CGB6/CGB7 and CGB8 [19, 27].

The results of our experiments demonstrated that both control and malignant ovarian tissues produce chorionic gonadotropin beta subunit transcripts. The expression of CGB3–9 genes was not only confirmed for all studied samples, but was also shown to be significantly higher in cancer than control ovarian tissue. This is consistent with previous reports on the prevalence of the transcriptional activity of CGB3–9 genes in malignant tissue when compared to benign changes or healthy tissues [19, 27]. CGB1 and CGB2 genes were detected to be transcriptionally active only in 20% of tested ovarian cancer tissues and at the lowest level across all tested CGB genes of the cluster. It is only recently, due to novel sensitive molecular techniques, that it has become possible to establish that these are active genes and not, as previously considered, pseudogenes [27–29]. In fact we previously demonstrated the presence of CGB1 and CGB2 transcripts in ovarian carcinomas [27]. Still, little is known about regulation of these genes expression and transcription factors assumed to regulate CGB1 and CGB2 expression were predicted using in silico analysis tools [30].

Associations between the expression of CGB genes and epigenetics have hitherto been studied only in normal placental tissue and it has been known for some time that the genome of placental tissue is characterized by a higher degree of hypomethylation compared to other healthy tissues; the CGB gene coding region is no exception to this [11–13, 31, 32]. Our previous study showed that CGB3–9 are the most transcriptionally

![Fig. 3](image.png)
active CGB genes in placenta and are hypomethylated. However, so are CGB1 and CGB2 promoter regions. Here we have shown a similar pattern of hypomethylation and increased transcription of CGB genes in ovarian cancer tissue. Notably transcription of CGB1 and CGB2 was detected in 20% of ovarian cancer samples. Additionally, our experiments revealed that the degree of methylation of CGB promoter regions correlates with the level of CGB transcripts in chorionic tissue and placenta. Thus, epigenetic changes may be considered a factor contributing to pregnancy failure [13]. By implication it may be speculated that the induction of CGB gene cluster methylation could contribute to the decrease in hCGβ expression by tumours, which may be advantageous to cancer patients.

The manner in which epigenetics influences carcinogenesis varies among different carcinomas. However, DNA hypomethylation or demethylation was the initial epigenetic aberration recognized in human tumours [33] and is still extensively studied as a phenomenon associated with the development and survival of cancer cells. In this context our results show that ovarian cancers are characterized by demethylation of the CGB genes compared to control ovary tissues.

There were no significant correlations between methylation status and expression level of particular CGB genes. This fact might be the consequence of the adopted methods. Even though RT-qPCR is a highly sensitive and accurate method, methylation specific PCR (MSP) is a semi-quantitative technique. Thus, combining data obtained using these two methods in the statistical analysis might not have yielded significant differences, although differences between healthy ovary and cancerous tissue were evident in both assays.

It has been shown, that for CGB gene transcription in placenta, the most important seems to be 360 nucleotides long 5’UTR region with binding sites of transcription factors such as: SP1, SP3 and AP2, which regulate basal CGB expression [13, 22, 26, 34, 35]. Our previous results revealed strong correlations between TFAP2A transcripts and CGB1–9 as well as CGB3–9 mRNA levels in term placenta [13]. In the present study conducted on cancer tissue, we confirm the significance of TFAP2A, as its higher expression in cancer tissues in contrast to normal ovary was noted. What is more strong positive correlation between the amount of the factor’s mRNA and that of CGB3–9 in this group has been shown.

The influence of SP1 and SP3 expression on CGB expression in cancer is very difficult to assess. The results showed that healthy ovaries and ovarian cancers did not differ in terms of SP1 transcription factor expression. On the other hand, ovarian tumours were characterized by significantly lower level of SP3 transcripts. The expression of these transcription factors did not correlate with CGB transcriptional activity. Still, it is known that SP1 and SP3 are factors which can extend opposite effects on CGB genes expression in trophoblast. Therefore, interpretation of the results obtained for cancers may not be so straightforward [22, 26]. Nevertheless, it cannot be excluded that similar mechanisms may regulate CGB gene expression during both pregnancy and in cancer.

Parallels between pregnancy development and cancer have been shown before. Malignant and trophoblastic cells share the ability to escape apoptosis, migrate and invade surrounding tissues while evading a host immune response [36]. Because of a common mechanisms influencing CGB genes expression in pregnancy and cancer shown in our studies, it can be expected that regulation of these processes might share some common features. Indeed, the results of the present study showed that, similar to the placenta, the expression of CGB genes in ovarian cancer strongly correlates with TFAP2A expression. Additionally both tissues are characterised by the demethylation of CGB promoters.

Further studies on the common pathways of CGB genes transcription regulation in trophoblast and malignant cells can lead to the development of novel diagnostic approaches for the early identification of both pathologies in pregnancy and cancer.

Conclusions
In ovarian cancers increased expression of human chorionic gonadotropin beta subunit is associated with demethylation of CGB promoter regions and CGB3–9 expression level strongly correlates with expression of TFAP2A transcription factor. This seems to point to a common mechanism of CGB expression regulation in placenta and ovarian cancer. Furthermore presence of mRNA arising from CGB1 and CGB2 genes appears to be a unique feature of a subset of ovarian cancers.

Abbreviations
5’UTR: 5’ untranslated region; AP2: Activating enhancer binding protein 2; alpha; βCG: Blackberry Quencher; CGB: human chorionic gonadotropin beta subunit gene; CGB1–2, NM: primers complementary to the non-methylated variant of CGB1–2 genes; CGB1–2, M: primers complementary to the methylated variant of CGB1–2 genes; CGB3–9, NM: primers complementary to the non-methylated variant of CGB3–9 genes; CGB3–9, M: primers complementary to the methylated variant of CGB3–9 genes; DAPK1: Death associated kinase 1 gene; ETS-2: protein C-ets-2; hCG: human chorionic gonadotropin; hCG β: human chorionic gonadotropin free beta subunit; HPRF: hypoxanthine-guanine phosphoribosyltransferase 1; MSP: methylation specific polymerase chain reaction; MTA3: metastasis-associated protein; OCT3/4: octamer-binding transcription factor 3/4; P53: tumor suppressor p53; PPARγ: peroxisome proliferator-activated receptor gamma; RT-qPCR: Reverse transcriptase quantitative polymerase chain reaction; SP1: Specificity protein 1; SP3: Specificity protein 3; TFAP2A: transcription factor AP2 gene; UICC: The Union for International Cancer Control

Acknowledgements
Not applicable
Authors’ contributions
A5 performed and analyzed the MSP studies, performed statistical analysis and wrote the manuscript. ASz and MK performed RT-qPCR studies, data analysis and drafting of the manuscript. PB and BB performed interpretation of data and drafting of the manuscript. GW performed and analysed the MSP studies. ENM provided clinical samples and histopathological analysis of ovarian cancer samples. SB and RI interpreted data and performed critical review of the manuscript. AJ designed the study, interpreted data and wrote the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by Polish National Science Centre (grant number NN 407 275 439 and NN 407 459 138). The granted funding allowed for the purchase of laboratory equipment and reagents necessary to conduct the study.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and on the website: http://www.katbolkom.ump.edu.pl/wp-content/uploads/repozytorium/RAW-DATA_J-Ovarian-Research_25072018.xlsx

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics review board of Poznan University of Medical Sciences (Resolution No. 748/08) and patients participated in the study after their written informed consent was obtained.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cell Biology, Poznan University of Medical Sciences, 5D Rokietnicka Street, 60-806 Poznan, Poland. 2Gynaecologic Oncology Department, Poznan University of Medical Sciences, 33 Polna Street, 60-101 Poznan, Poland. 3Centre for Investigative and Diagnostic Oncology, Middlesex University, The Burroughs, London NW4 4BT, UK. 4MAP Diagnostics Ltd, The iLAB, Stannard Way, Bedford, Bedfordshire MK44 3RZ, UK. 5College of Health, Abu Dhabi University, Abu Dhabi, United Arab Emirates.

Received: 8 November 2018 Accepted: 19 July 2019

Published online: 30 July 2019

References
1. Srisurarp S, Strakova Z, Fazleabas AT. The role of choriocarcinoma gonadotropin (CG) in blastocyst implantation. Arch Med Res. 2001;32(6):627–34.
2. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. Human chorionic gonadotropin contributes to maternal Imnuncorello and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003;171(S): 2930–3.
3. Herr F, Baal N, Reisinger K, Lorenz A, McKinnon T, Preissner KT, et al. hCG in the Regulation of Placental Angiogenesis. Results of an in Vitro Study. Placenta. IPPA and Elsevier Ltd. 2007;28(SUPPL A):S85–93.
4. Illes RK, Delves PJ, Butler SA. Does hCG or hCGβ play a role in cancer cell biology? Mol Cell Endocrinol. 2010;329(1–2):62–70.
5. Hamada AL, Nakabayashi K, Satoh A, Kyoshii K, Takamatsu Y, Laiang-Fernandez JB, et al. Transfection of antisense choriocarcinoma β gene into Choriocarcinoma cells suppresses the cell proliferation and induces apoptosis. J Clin Endocrinol Metab. 2005;90(8):4873–9.
6. Jankowski A, Gunderson SI, Andrusiewicz M, Burczynska B, Szczalba A, Jamolowski A, et al. Reduction of human choriocarcinoma β subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol Cancer. 2008;7:1–9.
7. Cole LA. HCG variants, the growth factors which drive human malignancies. Am J Cancer Res. 2012;2(1):22–35.
8. Liu N, Peng S-M, Zhan G-X, Yu J, Wu W-M, Gao H, et al. Human chorionic gonadotropin beta regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer. Oncol Rep. 2017;41:644–72.
9. Gao S, Fan C, Huang H, Zhu C, Su M, Zhang Y. Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo. Oncol Lett. 2016;12(1):459–66.
10. Campain JA, Gutkin DW, Cox GS. Differential DNA methylation of the choriocarcinoma β subunit multigene family. Mol Endocrinol. 1993;7(10):1331–46.
11. Grigoroiu A, Ferreira JC, Choufani S, Baczcy K, Kindon J, Webkberg R. Cell specific patterns of methylation in the human placenta. Epigenetics. 2011;6(3):368–79.
12. Usukula L, Ruhl K, Naginjina L, Laan M. Methylation allelic polymorphism (MAP) in choriocarcinoma β (βCGS) and its association with pregnancy success. J Clin Endocrinol Metab. 2011;96(1):199–207.
13. Godek A, Kubicka MJ, Walkowisk GP, Nowak-Markwitz E, Jankowska A. Methylation status of human chorionic gonadotropin β subunit promoter and TFAP2A expression as factors regulating CGB gene expression in placenta. Fertil Steril. 2014;102(4):1175–1182.e6.
14. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics. 2004;3(10):960–9.
15. Bartel DP. MicroRNA target recognition and regulatory functions. Cell. 2009;136(2):215–33.
16. Vogel C, De Sousa AR, Ko D, Le SY, Shapiro BA, Bums SC, et al. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol Nature Publishing Group. 2010;6(400):1–9.
17. Schwanhiisser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.
18. Talmadge K, Boonstein WR, Vamvakopoulos NC, Gething MJ, Fiddes JC. Only three of the seven human chorionic gonadotropin β subunit genes can be expressed in the placenta. Nucleic Acids Res. 1984;21(22):8415–36.
19. Hotakainen K, Lintula S, Jarvinen R, Paju A, Stenman J. Overexpression of human chorionic gonadotropin β subunit genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer patients. Tumor Biol. 2007;28(1):52–6.
20. Liu L, Roberts RM. Silencing of the gene for the beta subunit of human chorionic gonadotropin by the embryonic transcription factor Oct-3/4. J Biol Chem. 1996;271(28):16685–9.
21. Ghosh D, Ezashi T, Ostrowski MC, Roberts RM. A central role for Ets-2 in the transcriptional regulation and cyclic adenosine 3’-monophosphate responsiveness of the human chorionic gonadotropin-β subunit gene. Mol Endocrinol. 2003;17(11):11–26.
22. Knöfler M, Saleh L, Bauer S, Galos B, Rotheneder H, Husslein P, et al. Transcriptional regulation of the human chorionic gonadotropin β gene during villous trophoblast differentiation. Endocrinology. 2004;145(4):1685–94.
23. Fournier T, Guibourdenche J, Handschuh K, Tsatsaris V, Rauwel B, Davrinche C, et al. PPARy and human trophoblast differentiation. J Reprod Immunol. 2011;90(1):41–9.
24. Sohr S, Engeland K. The tumor suppressor p53 induces expression of the pregnancy-supporting human chorionic gonadotropin (hCG) CGB gene. Cell Cycle. 2011;10(21):3758–67.
25. Chen Y, Miyazaki J, Nishizawa H, Kurahashi H, Leach R, Wang K. MTA3 regulates CGB5 and snail genes in trophoblast. Biochem Biophys Res Commun. 2013;434(3):379–84.
26. Adams C, Henke A, Gromoll J. A novel two-promoter-one-gene system of the chorionic gonadotropin β gene enables tissue-specific expression. J Mol Endocrinol. 2011;47(3):285–98.
27. Kubicka MJ, Walkowisk GP, Nowak-Markwitz E, Jankowska A. Human chorionic gonadotropin β subunit genes CGB1 and CGB2 are transcriptionally active in ovarian cancer. Int J Mol Sci. 2013;14(6):2650–60.
28. Burczynska BB, Kobrouly L, Butler SA, Naase M, Ies RK. Novel insights into the expression of CGB-1, 2 genes by epithelial cancer cell lines secreting ectopic free. Anticancer Res. 2014;34(5):2239–48.
29. Rull K, Hallast P, Usukula L, Jackson J, Punjab-M, Salunets A, et al. Fine-scale quantification of HCG β gene transcription in human trophoblastic and non-malignant non-trophoblastic tissues. Mol hum Reprod. 2008;14(1):23–31.
30. Rull K, Hallast P, Laan M. The evolution and genomic landscape of CGB1 and CGB2 genes. Mol Cell Endocrinol Elsevier Ireland Ltd. 2007;260–262(1): 2–11.
31. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucleic Acids Res. 1982;10(8):2709–21.
32. Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet. 2004;68(3):196–204.
33. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983;11(19):6883–94.
34. Biadasiewicz K, Sonderegger S, Haslinger P, Haider S, Saleh L, Fiala C, et al. Transcription factor AP-2α promotes EGF-dependent invasion of human trophoblast. Endocrinology. 2011;152(4):1458–69.
35. Chen L, Zhu H, Pan Y, Tang C, Watanabe M, Ruan H, et al. Ascorbic acid uptake by sodium-dependent vitamin C transporter 2 induces hCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells. J Clin Endocrinol Metab. 2012;97(9):1667–76.
36. Enninga EAL, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, et al. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc. 2014;89(4):520–35.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.